pseudomyxoma peritonei

Summary

Summary: A condition characterized by poorly-circumscribed gelatinous masses filled with malignant mucin-secreting cells. Forty-five percent of pseudomyxomas arise from the ovary, usually in a mucinous cystadenocarcinoma (CYSTADENOCARCINOMA, MUCINOUS), which has prognostic significance. Pseudomyxoma peritonei must be differentiated from mucinous spillage into the peritoneum by a benign mucocele of the appendix. (Segen, Dictionary of Modern Medicine, 1992)

Top Publications

  1. Smeenk R, Verwaal V, Zoetmulder F. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei--a report of 103 procedures. Eur J Surg Oncol. 2006;32:186-90 pubmed
    To report on treatment related toxicity and mortality in patients with pseudomyxoma peritonei (PMP) treated by cytoreduction in combination with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) and to identify prognostic ..
  2. Sulkin T, O NEILL H, Amin A, Moran B. CT in pseudomyxoma peritonei: a review of 17 cases. Clin Radiol. 2002;57:608-13 pubmed
    To describe the computed tomography (CT) findings in pseudomyxoma peritonei. Two observers independently and retrospectively reviewed the CT images of 17 consecutive patients (nine women, eight men, mean age 53 years) with histologically ..
  3. Moran B, Baratti D, Yan T, Kusamura S, Deraco M. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol. 2008;98:277-82 pubmed publisher
    b>Pseudomyxoma peritonei (PMP) is a rare condition mostly originating from low malignant potential mucinous tumours of the appendix...
  4. Hosaka A, Masaki Y, Yamasaki K, Aoki F, Sugizaki K. Pseudomyxoma peritonei presenting with femoral hernias and peritonitis. J Gastrointest Surg. 2007;11:1576-8 pubmed
    b>Pseudomyxoma peritonei is a rare disease characterized by intraperitoneal accumulation of mucinous ascites produced by neoplastic cells, which mostly originate from an appendiceal adenoma...
  5. Witkamp A, de Bree E, Kaag M, van Slooten G, van Coevorden F, Zoetmulder F. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg. 2001;88:458-63 pubmed
    b>Pseudomyxoma peritonei remains a fatal disease...
  6. Smeenk R, Bex A, Verwaal V, Horenblas S, Zoetmulder F. Pseudomyxoma peritonei and the urinary tract: involvement and treatment related complications. J Surg Oncol. 2006;93:20-3 pubmed
    b>Pseudomyxoma peritonei (PMP) is a rare clinical syndrome characterized by intraperitoneal accumulation of mucus produced by neoplastic cells of mostly appendiceal origin...
  7. Andreasson H, Graf W, Nygren P, Glimelius B, Mahteme H. Outcome differences between debulking surgery and cytoreductive surgery in patients with Pseudomyxoma peritonei. Eur J Surg Oncol. 2012;38:962-8 pubmed publisher
    The aim of this study was to compare debulking surgery and cytoreductive surgery (CRS) in patients with Pseudomyxoma peritonei (PMP) regarding efficacy and safety...
  8. Galani E, Marx G, Steer C, Culora G, Harper P. Pseudomyxoma peritonei: the 'controversial' disease. Int J Gynecol Cancer. 2003;13:413-8 pubmed
    b>Pseudomyxoma peritonei (PMP) is a rare disease that is characterized by a large amount of mucinous ascites with peritoneal and omental implants. The etiology of the disease remains unclear...
  9. Murphy E, Sexton R, Moran B. Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm. Dis Colon Rectum. 2007;50:37-42 pubmed
    ..Occult rupture with features of pseudomyxoma peritonei may be encountered...

More Information

Publications88

  1. Dixit A, Robertson J, Mudan S, Akle C. Appendiceal mucocoeles and pseudomyxoma peritonei. World J Gastroenterol. 2007;13:2381-4 pubmed
    ..or iatrogenic rupture of the mucocoele can lead to mucinous intraperitoneal ascites, a syndrome known as pseudomyxoma peritonei. Optimal management of mucoceles is achieved through accurate preoperative identification and subsequent ..
  2. Flatmark K, Davidson B, Kristian A, Stavnes H, Førsund M, Reed W. Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models. Hum Pathol. 2010;41:1109-19 pubmed publisher
    ..Five human tumors and corresponding orthotopic animal models of human pseudomyxoma peritonei and peritoneal mucinous carcinomatosis from colorectal carcinoma were extensively characterized by ..
  3. Misdraji J. Appendiceal mucinous neoplasms: controversial issues. Arch Pathol Lab Med. 2010;134:864-70 pubmed publisher
    Low grade appendiceal mucinous neoplasms can spread to the peritoneum as pseudomyxoma peritonei even though they are not obviously invasive in the appendix...
  4. Stenhouse G, McRae D, Pollock A. Urachal adenocarcinoma in situ with pseudomyxoma peritonei: a case report. J Clin Pathol. 2003;56:152-3 pubmed
    ..At laparotomy, pseudomyxoma peritonei was discovered, together with a midline abdominal mass adherent to the anterior abdominal wall originating ..
  5. Sugarbaker P. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol. 2001;27:239-43 pubmed
    ..b>Pseudomyxoma peritonei may be especially appropriate for these aggressive local regional treatments...
  6. Jayaraman S, Moussa M, Gray D. Soft-tissue images. Pseudomyxoma peritonei and villous adenoma of the appendix. Can J Surg. 2002;45:90-1 pubmed
  7. Szych C, Staebler A, Connolly D, Wu R, Cho K, Ronnett B. Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women. Am J Pathol. 1999;154:1849-55 pubmed
    b>Pseudomyxoma peritonei (PMP) is a poorly understood condition characterized by mucinous ascites and multifocal peritoneal mucinous tumors. Women with PMP often have mucinous tumors involving both the appendix and the ovaries...
  8. Saxena A, Yan T, Chua T, Morris D. Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2010;17:1291-301 pubmed publisher
    ..intraperitoneal chemotherapy (PIC) has demonstrated improved survival in selected patients with pseudomyxoma peritonei (PMP)...
  9. Güner Z, Schmidt U, Dahlke M, Schlitt H, Klempnauer J, Piso P. Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Int J Colorectal Dis. 2005;20:155-60 pubmed
    Surgical improvement can be achieved in selected patients with pseudomyxoma peritonei (PMP) by major cytoreductive surgery and intraperitoneal chemotherapy (IPEC)...
  10. van Ruth S, Acherman Y, van de Vijver M, Hart A, Verwaal V, Zoetmulder F. Pseudomyxoma peritonei: a review of 62 cases. Eur J Surg Oncol. 2003;29:682-8 pubmed
    b>Pseudomyxoma peritonei (PMP) is a rare disease characterized by the abundance of mucus in the abdomen without extra-peritoneal growth...
  11. Bibi R, Pranesh N, Saunders M, Wilson M, O Dwyer S, Stern P, et al. A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei. Br J Cancer. 2006;95:1258-64 pubmed
    b>Pseudomyxoma peritonei (PMP) is a rare neoplasm of mainly appendiceal origin, characterised by excess intra-abdominal mucin production leading to high morbidity and mortality...
  12. Gilbreath J, Semino Mora C, Friedline C, Liu H, Bodi K, McAvoy T, et al. A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei. Orphanet J Rare Dis. 2013;8:105 pubmed publisher
    b>Pseudomyxoma peritonei (PMP) is a malignancy characterized by dissemination of mucus-secreting cells throughout the peritoneum...
  13. Fairise A, Barbary C, Derelle A, Tissier S, Granger P, Marchal F, et al. [Mucocele of the appendix and pseudomyxoma peritonei]. J Radiol. 2008;89:751-62 pubmed
  14. Vana J, Adamicova K, Johanes R, Zacharova O, Ammerová E, Solek R. [Appendiceal mucocele causing pseudomyxoma peritonei]. Zentralbl Chir. 2005;130:177-80 pubmed
    The authors present the case of a very rare pseudomyxoma peritonei as a late complication of appendectomy. The definite diagnosis was established 11 years after appendectomy for appendiceal mucocele...
  15. Yan H, Pestieau S, Shmookler B, Sugarbaker P. Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation. Mod Pathol. 2001;14:164-71 pubmed
    b>Pseudomyxoma peritonei syndrome is a disease characterized by mucinous ascites and mucinous tumor disseminated on peritoneal surfaces; the disease almost always originates from a perforated appendiceal epithelial tumor...
  16. Kusamura S, Hutanu I, Baratti D, Deraco M. Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei. J Surg Oncol. 2013;108:1-8 pubmed publisher
    Incomplete cytoreduction (IC) is one of the main prognostic factor in pseudomyxoma peritonei (PMP). We evaluated the ability of preoperative Ca125, CEA, and Ca19-9 to predict IC and prognosis in PMP...
  17. Shetty S, Thomas P, Ramanan B, Sharma P, Govindarajan V, Loggie B. Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis. J Surg Res. 2013;180:97-103 pubmed publisher
    Little information exists on Kras mutations and p53 overexpression in pseudomyxoma peritonei (PMP). These genetic alterations are associated with poorer prognoses in colorectal cancer...
  18. Yan T, Black D, Savady R, Sugarbaker P. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2007;14:484-92 pubmed
    The efficacy of cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) for patients with pseudomyxoma peritonei (PMP) remains to be established.
  19. Shimoyama S, Kuramoto S, Kawahara M, Yamasaki K, Endo H, Murakami T, et al. A rare case of pseudomyxoma peritonei presenting an unusual inguinal hernia and splenic metastasis. J Gastroenterol Hepatol. 2001;16:825-9 pubmed
    b>Pseudomyxoma peritonei (PMP) is a rare clinical entity in which a diffuse collection of intraperitoneal gelatinous fluid is associated with gelatinous implants on the peritoneal surfaces and omentum...
  20. Pai R, Longacre T. Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems, and proposed classification. Adv Anat Pathol. 2005;12:291-311 pubmed
    b>Pseudomyxoma peritonei is an overused and underspecified condition that has garnered much attention in the historic literature...
  21. Mohamed F, Gething S, Haiba M, Brun E, Sugarbaker P. Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process. J Surg Oncol. 2004;86:10-5 pubmed
    Three distinct morphologic types of pseudomyxoma peritonei syndrome have been defined: disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinoma (PMCA), and a hybrid morphologic type...
  22. Rezkalla M, Peterson K, Ryan J. Pseudomyxoma peritonei: a case of mucinous adenocarcinoma of the appendix presenting as inguinal hernia. S D Med. 2006;59:54-5, 57 pubmed
    b>Pseudomyxoma peritonei is a rare neoplastic condition characterized by diffuse collections of gelatinous fluid associated with mucinous implants on the peritoneal surfaces and omentum...
  23. Haase E, Yoo D, Sugarbaker P. Management of appendiceal pseudomyxoma peritonei diagnosed during pregnancy. World J Surg Oncol. 2009;7:48 pubmed publisher
    ..Epithelial tumors of the appendix on the other hand are rare and account for only approximately 1% of all colorectal neoplasms; the occurrence of this neoplasm during pregnancy is extremely rare...
  24. Loungnarath R, Causeret S, Brigand C, Gilly F, Glehen O. [Pseudomyxoma peritonei: new concept and new therapeutic approach]. Ann Chir. 2005;130:63-9 pubmed
    b>Pseudomyxoma peritonei is a rare disease, usually diagnosed after the discover of "jelly belly" by laparotomy...
  25. Kirby R, Liauw W, Zhao J, Morris D. Quality of life study following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei including redo procedures. Int J Surg Oncol. 2013;2013:461041 pubmed publisher
    ..was to evaluate the quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. We also conducted an analysis of all patients who underwent CRS and HIPEC for pseudomyxoma peritonei from ..
  26. Semino Mora C, Testerman T, Liu H, Whitmire J, Studeman K, Jia Y, et al. Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects ?-catenin distribution. Clin Cancer Res. 2013;19:3966-76 pubmed publisher
    b>Pseudomyxoma peritonei is an understudied cancer in which an appendiceal neoplasm invades the peritoneum and forms tumor foci on abdominal organs...
  27. Smeenk R, Verwaal V, Antonini N, Zoetmulder F. Progression of pseudomyxoma peritonei after combined modality treatment: management and outcome. Ann Surg Oncol. 2007;14:493-9 pubmed
    ..surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment strategy for pseudomyxoma peritonei (PMP) with curative intent...
  28. Ronnett B, Seidman J. Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei. Am J Surg Pathol. 2003;27:650-7 pubmed
    Recent studies have redefined pseudomyxoma peritonei (PMP) as a specific clinicopathologic syndrome in which mucinous ascites is accompanied by peritoneal lesions characterized by bland to low-grade adenomatous mucinous epithelium ..
  29. O Connell J, Tomlinson J, Roberts A, McGonigle K, Barsky S. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. Am J Pathol. 2002;161:551-64 pubmed
    b>Pseudomyxoma peritonei, a syndrome first described by Karl F...
  30. Passot G, Glehen O, Pellet O, Isaac S, Tychyj C, Mohamed F, et al. Pseudomyxoma peritonei: role of 18F-FDG PET in preoperative evaluation of pathological grade and potential for complete cytoreduction. Eur J Surg Oncol. 2010;36:315-23 pubmed publisher
    For pseudomyxoma peritonei (PMP), survival depends on pathological grade and completeness of cytoreductive surgery. The aim of the study was to assess the ability of preoperative 18F-FDG PET to determine these 2 prognosis indicators.
  31. Heiskala K, Giles Komar J, Heiskala M, Andersson L. High expression of RELP (Reg IV) in neoplastic goblet cells of appendiceal mucinous cystadenoma and pseudomyxoma peritonei. Virchows Arch. 2006;448:295-300 pubmed
    ..RELP in the neoplastic goblet cells of appendiceal mucinous cystadenomas and in the epithelial implants of pseudomyxoma peritonei (PMP)...
  32. Pranesh N, Menasce L, Wilson M, O Dwyer S. Pseudomyxoma peritonei: unusual origin from an ovarian mature cystic teratoma. J Clin Pathol. 2005;58:1115-7 pubmed
    b>Pseudomyxoma peritonei (PMP) is classified into pathologically and prognostically distinct categories, such as disseminated peritoneal adenomucinosis (DPAM) and peritoneal mucinous carcinomatosis...
  33. Ghidirim G, Mishin I, Zastavnitsky G. Pseudomyxoma peritonei presenting with inguinal hernia. Chirurgia (Bucur). 2011;106:527-9 pubmed
    b>Pseudomyxoma peritonei (PMP) is rare being characterized by intraperitoneal accumulation of mucinous ascites produced by neoplastic cells, mostly originating from a perforated appendiceal adenoma...
  34. Ferreira C, Carvalho J, Soares F, Siqueira S, Carvalho F. Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors. Int J Gynecol Cancer. 2008;18:59-65 pubmed
    b>Pseudomyxoma peritonei (PMP) is a clinical condition initially thought to be related to ovarian mucinous tumors; however, immunohistochemistry and molecular biology techniques have convincingly made the link to appendiceal mucinous ..
  35. Baratti D, Kusamura S, Nonaka D, Cabras A, Laterza B, Deraco M. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2009;249:243-9 pubmed publisher
    ..To investigate outcome and prognostic factors in patients with pesudomyxoma peritonei (PMP) treated by complete cytoreduction and hyperthermic intraperitoneal chemotherapy...
  36. Mall A, Chirwa N, Govender D, Lotz Z, Tyler M, Rodrigues J, et al. MUC2, MUC5AC and MUC5B in the mucus of a patient with pseudomyxoma peritonei: biochemical and immunohistochemical study. Pathol Int. 2007;57:537-47 pubmed
    A 58-year-old man with a 1 year history of progressive abdominal distension underwent a laparotomy for pseudomyxoma peritonei. The mucin was identified and characterized in the present study...
  37. Jess P, Iversen L, Nielsen M, Hansen F, Laurberg S, Rasmussen P. Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study. Dis Colon Rectum. 2008;51:868-74 pubmed publisher
    The modern treatment of pseudomyxoma peritonei is cytoreductive surgery plus intraperitoneal chemotherapy resulting in a survival of up to 70 percent after 20 years...
  38. McBride K, McFadden D, Osler T. Improved survival of patients with pseudomyxoma peritonei receiving intraperitoneal chemotherapy with cytoreductive surgery: a systematic review and meta-analysis. J Surg Res. 2013;183:246-52 pubmed publisher
    b>Pseudomyxoma peritonei (PMP) is an uncommon but lethal variant of adenocarcinoma...
  39. Guo A, Song X, Wei L, Zhao P. Histological origin of pseudomyxoma peritonei in Chinese women: clinicopathology and immunohistochemistry. World J Gastroenterol. 2011;17:3531-7 pubmed publisher
    To investigate the histological origin of pseudomyxoma peritonei (PMP) in Chinese women.
  40. Ronnett B, Zahn C, Kurman R, Kass M, Sugarbaker P, Shmookler B. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei&. Am J Surg Pathol. 1995;19:1390-408 pubmed
    b>Pseudomyxoma peritonei (PMP) is a poorly understood condition characterized by mucinous ascites and mucinous implants diffusely involving the peritoneal surfaces...
  41. Moran B, Cecil T. The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg Oncol Clin N Am. 2003;12:585-603 pubmed
    ..Sugarbaker has suggested "the term pseudomyxoma peritonei syndrome be strictly applied to a pathologically and prognostically homogenous group of cases ..
  42. Geisinger K, Levine E, Shen P, Bradley R. Pleuropulmonary involvement in pseudomyxoma peritonei: morphologic assessment and literature review. Am J Clin Pathol. 2007;127:135-43 pubmed
    Intrathoracic spread in patients with pseudomyxoma peritonei (PP) is rare. We reviewed 101 patients uniformly treated at our institution for PP of appendiceal origin...
  43. Ronnett B, Shmookler B, Sugarbaker P, Kurman R. Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol. 1997;2:197-226 pubmed
    ..Tumors exhibiting the features currently interpreted as borderline should be included in the benign group and designated atypical proliferative mucinous tumors...
  44. Samet I, Cormier B, Mowlawi H, Philippe A, Arbion F, Fetissof F. [Endometrial and endocervical lesions associated with pseudomyxoma peritonei: a case report]. Ann Pathol. 2009;29:233-7 pubmed publisher
    The association of a pseudomyxoma peritonei with a mucinous tumor of the appendix and/or the ovary is regularly reported in the literature. However, in this context, endometrial or endocervical lesions remain exceptional...
  45. Meshikhes A, Al Abkari H, Al momen S, Saad F. Pseudomyxoma peritonei. Saudi Med J. 2006;27:389-91 pubmed
    b>Pseudomyxoma peritonei is very rare, and its exact pathogenesis is unknown. It is characterized by intra-abdominal extracellular gelatinous fluid collections...
  46. Abdu B, Hobgood D, Stallings S, DePasquale S. Incidental finding of pseudomyxoma peritonei at primary cesarean section. Am J Perinatol. 2009;26:633-5 pubmed publisher
    ..may rupture, leading to intraperitoneal seeding of the peritoneum and producing the clinical picture of pseudomyxoma peritonei (PMP)...
  47. Chua T, Yan T, Smigielski M, Zhu K, Ng K, Zhao J, et al. Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol. 2009;16:1903-11 pubmed publisher
    ..CRS) and perioperative intraperitoneal chemotherapy (PIC) has been recognized as a treatment option for pseudomyxoma peritonei. This study reports the survival outcomes, clinicopathological prognostic factors, and a learning curve ..
  48. Bradley R, Stewart J, Russell G, Levine E, Geisinger K. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol. 2006;30:551-9 pubmed
    b>Pseudomyxoma peritonei is a clinical term for gelatinous ascites, usually secondary to an appendiceal tumor...
  49. Chua T, Yan T, Yap Z, Horton M, Fermanis G, Morris D. Thoracic cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy for pseudomyxoma peritonei. J Surg Oncol. 2009;99:292-5 pubmed publisher
    Pleural dissemination of pseudomyxoma peritonei (PMP) is considered an advanced/terminal disease...
  50. Maheshwari V, Tsung A, Lin Y, Zeh H, Finkelstein S, Bartlett D. Analysis of loss of heterozygosity for tumor-suppressor genes can accurately classify and predict the clinical behavior of mucinous tumors arising from the appendix. Ann Surg Oncol. 2006;13:1610-6 pubmed
    b>Pseudomyxoma peritonei is a rare heterogenous clinical syndrome with a variable clinical course...
  51. Kinkor Z, Michal M. [Syndrome of pseudomyxoma peritonei--description of three cases and survey of the problem]. Ceska Gynekol. 2005;70:67-72 pubmed
    To describe personal experience with three heterogeneous cases of pseudomyxoma peritonei. Review of the literature concentrates on the pathogenesis and biologic spectrum of the rare syndrome.
  52. Deraco M, Baratti D, Inglese M, Allaria B, Andreola S, Gavazzi C, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol. 2004;11:393-8 pubmed
    b>Pseudomyxoma peritonei (PMP) is a rare disease with a poor prognosis characterized by a complete redistribution of mucin within the peritoneal cavity...
  53. Taii A, Sakagami J, Shinoda M, Taniguchi H, Tosa M, Baba T, et al. Pseudomyxoma peritonei occurring after an uneventful 23 years interval from appendectomy. Intern Med. 2007;46:1109-12 pubmed
    ..He then received 3 courses of chemotherapy, but failed to reach a remission. The final diagnosis of pseudomyxoma peritonei was made by means of abdominocentesis, and he underwent debulking surgery...
  54. Alves S, Mohamed F, Yadegarfar G, Youssef H, Moran B. Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Eur J Surg Oncol. 2010;36:1156-61 pubmed publisher
    b>Pseudomyxoma peritonei (PMP) is characterized by mucinous ascites, predominantly arising form a perforated tumour of the appendix...
  55. Eisele L, Sheu S, Müller Beissenhirtz H, Welt A, Seeber S. Response of pseudomyxoma peritonei to gemcitabine. Acta Oncol. 2006;45:98-100 pubmed
  56. Kotani Y, Shiota M, Umemoto M, Tobiume T, Koike E, Shimaoka M, et al. Laparoscopic mucin removal in patients with pseudomyxoma peritonei. JSLS. 2009;13:203-6 pubmed
    b>Pseudomyxoma peritonei results from ovarian and appendiceal mucinous tumors. Cyst rupture results in intraabdominal mucin accumulation, leading to abdominal distension. No effective treatment has yet been established...
  57. Youssef H, Newman C, Chandrakumaran K, Mohamed F, Cecil T, Moran B. Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin. Dis Colon Rectum. 2011;54:293-9 pubmed publisher
    b>Pseudomyxoma peritonei syndrome is a clinical entity characterized by mucinous ascites usually originating from a perforated mucinous appendiceal tumor...
  58. Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva D, et al. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2007;14:2300-8 pubmed
    Encouraging results have been recently reported in selected patients affected by pseudomyxoma peritonei (PMP) treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)...
  59. Vaira M, Cioppa T, De Marco G, Bing C, D Amico S, D Alessandro M, et al. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience. In Vivo. 2009;23:639-44 pubmed
    b>Pseudomyxoma peritonei (PMP) is a rare peritoneal carcinomatosis, characterized by a slowly progressive disease process with a large amount of mucus containing occasional epithelial cells...
  60. Shah V, Amonkar G, Deshpande J, Bhalekar H. Mucinous adenocarcinoma of the renal pelvis with pseudomyxoma peritonei. Indian J Pathol Microbiol. 2008;51:536-7 pubmed
    ..b>Pseudomyxoma peritonei is an uncommon condition characterized by the presence of mucinous gelatinous material in the peritoneal ..
  61. Semino Mora C, Liu H, McAvoy T, Nieroda C, Studeman K, Sardi A, et al. Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. Ann Surg Oncol. 2008;15:1414-23 pubmed publisher
    b>Pseudomyxoma peritonei (PMP) is characterized by peritoneal tumors arising from a perforated appendiceal adenoma or adenocarcinoma, but associated entry of enteric bacteria in the peritoneum has not been considered as a cofactor...
  62. Baratti D, Kusamura S, Nonaka D, Langer M, Andreola S, Favaro M, et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2008;15:526-34 pubmed
    ..hyperthermic intraperitoneal chemotherapy (HIPEC) has been recently advocated as the standard of care for pseudomyxoma peritonei (PMP)...
  63. Landen S, Bertrand C, Maddern G, Herman D, Pourbaix A, de Neve A, et al. Appendiceal mucoceles and pseudomyxoma peritonei. Surg Gynecol Obstet. 1992;175:401-4 pubmed
    Mucoceles of the appendix and associated pseudomyxoma peritonei are a heterogeneous group comprising various histopathologic lesions with differing prognoses...
  64. Shetty S, Natarajan B, Thomas P, Govindarajan V, Sharma P, Loggie B. Proposed classification of pseudomyxoma peritonei: influence of signet ring cells on survival. Am Surg. 2013;79:1171-6 pubmed
    The nomenclature and classification of pseudomyxoma peritonei (PMP) is confusing and controversial. Numerous classification systems have been proposed, none of which are easily reproducible or a useful guide for treatment...
  65. van Ruth S, Hart A, Bonfrer J, Verwaal V, Zoetmulder F. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2002;9:961-7 pubmed
    ..9 (CA19.9) measurements in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
  66. Gough D, Donohue J, Schutt A, Gonchoroff N, Goellner J, Wilson T, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg. 1994;219:112-9 pubmed
    The aims of this study were to analyze the natural history of patients with pseudomyxoma peritonei (PMP), evaluate clinical and pathologic variables as prognostic indicators, and review the authors' experience with different treatments.
  67. Dang A, Mansfield P, Ilsin B, Hightower C, Aravindan N, Rice D, et al. Intraoperative hyperthermic intrathoracic chemotherapy for pleural extension of pseudomyxoma peritonei. J Cardiothorac Vasc Anesth. 2007;21:265-8 pubmed
  68. Mukherjee A, Parvaiz A, Cecil T, Moran B. Pseudomyxoma peritonei usually originates from the appendix: a review of the evidence. Eur J Gynaecol Oncol. 2004;25:411-4 pubmed
    b>Pseudomyxoma peritonei (PMP) is a rare condition, said to be more common in females during the fourth or fifth decade of life with an incidence believed to be in the region of one per million per year...
  69. Miner T, Shia J, Jaques D, Klimstra D, Brennan M, Coit D. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. 2005;241:300-8 pubmed
    b>Pseudomyxoma peritonei (PMP) is a clinical syndrome with a poorly defined natural history. Relative contributions of tumor biology, patient selection, and the extent of treatment on ultimate outcome are not well characterized.
  70. Bryant J, Clegg A, Sidhu M, Brodin H, Royle P, Davidson P. Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei. Br J Surg. 2005;92:153-8 pubmed
    b>Pseudomyxoma peritonei, a rare progressive disease process within the peritoneum, is characterized by an abundance of mucinous fluid; if left untreated, the condition is fatal...
  71. Elias D, Gilly F, Quenet F, Bereder J, Sideris L, Mansvelt B, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2010;36:456-62 pubmed publisher
    To analyze a large series of patients with pseudomyxoma peritonei (PMP) treated with cytoreductive surgery associated with perioperative intraperitoneal chemotherapy (PIC) in 18 French-speaking centers.
  72. Qu Z, Liu L. Management of pseudomyxoma peritonei. World J Gastroenterol. 2006;12:6124-7 pubmed
    b>Pseudomyxoma peritonei (PMP) is a rare disease...
  73. Lee J, Song S, Kim I, Lee K, Kim B, Kim J, et al. Retrospective multicenter study of a clinicopathologic analysis of pseudomyxoma peritonei associated with ovarian tumors (KGOG 3005). Int J Gynecol Cancer. 2008;18:916-20 pubmed publisher
    The purpose of this study is to assess clinicopathologic features of pseudomyxoma peritonei (PMP) that has ovarian pathology and its relationship with the prognosis...
  74. Smeenk R, Verwaal V, Zoetmulder F. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg. 2007;94:1408-14 pubmed
    ..Cytoreductive surgery with intraperitoneal chemotherapy has emerged as a new standard approach for peritoneal surface disease. This study investigated the learning curve of this combined modality treatment at a single institute...
  75. Pitiakoudis M, Tsaroucha A, Mimidis K, Polychronidis A, Minopoulos G, Simopoulos C. Mucocele of the appendix: a report of five cases. Tech Coloproctol. 2004;8:109-12 pubmed
    ..Mucocele is often associated with concomitant colon cancer, thus patients with this tumor should be systematically checked for other colonic lesions...
  76. Chua T, Liauw W, Zhao J, Morris D. Upfront compared to delayed cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei is associated with considerably lower perioperative morbidity and recurrence rate. Ann Surg. 2011;253:769-73 pubmed publisher
    ..combined with perioperative intraperitoneal chemotherapy (PIC) is a recognized management strategy for pseudomyxoma peritonei. We seek to evaluate the outcomes of patients treated upfront with CRS PIC compared to patients undergoing ..
  77. Alexander Sefre F, Chandrakumaran K, Banerjee S, Sexton R, Thomas J, Moran B. Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence. Colorectal Dis. 2005;7:382-6 pubmed
    To assess the potential value of pre-operative CEA, CA 125 and CA 19-9 in identifying Pseudomyxoma peritonei (PMP) patients at risk of recurrence following complete cytoreductive surgery and intraperitoneal chemotherapy.
  78. Benoit L, Cheynel N, Ortega Deballon P, Giacomo G, Chauffert B, Rat P. Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs. Ann Surg Oncol. 2008;15:542-6 pubmed
    ..With open-abdomen HIPEC, the opposite is true. Although the open-abdomen method is potentially more effective, it has not become a standard procedure because of the risk of exposure of members of the team to drugs...
  79. Dayal S, Taflampas P, Riss S, Chandrakumaran K, Cecil T, Mohamed F, et al. Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved. Dis Colon Rectum. 2013;56:1366-72 pubmed publisher
    b>Pseudomyxoma peritonei is a diffuse peritoneal malignancy that generally originates form a perforated appendiceal tumor...